Pharmaceutical Executive Europe - January 2008 - (Page 25)

Pharmaceutical Executive Europe January 2008 Pricing and Reimbursement 25 Through the Reimbursement Barriers Brian Lovatt looks at how drug companies involved in oncology can meet their pricing and reimbursement objectives as NICE-style barriers start to rise across Europe. he focus on research and development of new anti-cancer treatments is likely to produce between 50 and 55 new approved NCEs in the next five years. This is fantastic news for the sufferers of cancer, their families and friends. But the problem is, will they be approved for reimbursement? On the positive side, the cancer therapeutic area budget stood at $35 billion in 2006, double that of 2001. Should all things be equal, we can expect the market to grow 17% to 20% through to the year 2010, which will make it worth between $62 and US$70 billion.1 However, a review of the drug budgets of all world’s major countries reveals there is going to be very little additional money available to pay for all the relatively-more-expensive cancer treatments that will be approved. More money to invest in healthcare needs to be found. The number of blockbuster drugs T ok.com/nxtbooks/advanstaruk/pharmexeceurope-imsoncology0907/index.php?startpage=2

Table of Contents Feed for the Digital Edition of Pharmaceutical Executive Europe - January 2008

Pharmaceutical Executive Europe - January 2008 Contents From the Editor News and Analysis Calendar Corporate Strategy: Walking the Line Executive Profile: The Pharmacist’s Friend Q&A: An End to Drug Counterfeiting Healthcare Cost Assessment: Ready to Make NICE? Pricing and Reimbursement: Through the Reimbursement Barriers Generics: India Inc. The Mix: New Models of Excellence Last Word: Mid-size Matters

Pharmaceutical Executive Europe - January 2008

Pharmaceutical Executive Europe - January 2008 - Pharmaceutical Executive Europe - January 2008 (Page 1) Pharmaceutical Executive Europe - January 2008 - Pharmaceutical Executive Europe - January 2008 (Page 2) Pharmaceutical Executive Europe - January 2008 - Contents (Page 3) Pharmaceutical Executive Europe - January 2008 - From the Editor (Page 4) Pharmaceutical Executive Europe - January 2008 - From the Editor (Page 5) Pharmaceutical Executive Europe - January 2008 - News and Analysis (Page 6) Pharmaceutical Executive Europe - January 2008 - News and Analysis (Page 7) Pharmaceutical Executive Europe - January 2008 - News and Analysis (Page 8) Pharmaceutical Executive Europe - January 2008 - News and Analysis (Page 9) Pharmaceutical Executive Europe - January 2008 - News and Analysis (Page 10) Pharmaceutical Executive Europe - January 2008 - News and Analysis (Page 11) Pharmaceutical Executive Europe - January 2008 - Calendar (Page 12) Pharmaceutical Executive Europe - January 2008 - Calendar (Page 13) Pharmaceutical Executive Europe - January 2008 - Corporate Strategy: Walking the Line (Page 14) Pharmaceutical Executive Europe - January 2008 - Corporate Strategy: Walking the Line (Page 15) Pharmaceutical Executive Europe - January 2008 - Corporate Strategy: Walking the Line (Page 16) Pharmaceutical Executive Europe - January 2008 - Corporate Strategy: Walking the Line (Page 17) Pharmaceutical Executive Europe - January 2008 - Executive Profile: The Pharmacist’s Friend (Page 18) Pharmaceutical Executive Europe - January 2008 - Executive Profile: The Pharmacist’s Friend (Page 19) Pharmaceutical Executive Europe - January 2008 - Q&A: An End to Drug Counterfeiting (Page 20) Pharmaceutical Executive Europe - January 2008 - Q&A: An End to Drug Counterfeiting (Page 21) Pharmaceutical Executive Europe - January 2008 - Healthcare Cost Assessment: Ready to Make NICE? (Page 22) Pharmaceutical Executive Europe - January 2008 - Healthcare Cost Assessment: Ready to Make NICE? (Page 23) Pharmaceutical Executive Europe - January 2008 - Healthcare Cost Assessment: Ready to Make NICE? (Page 24) Pharmaceutical Executive Europe - January 2008 - Pricing and Reimbursement: Through the Reimbursement Barriers (Page 25) Pharmaceutical Executive Europe - January 2008 - Pricing and Reimbursement: Through the Reimbursement Barriers (Page 26) Pharmaceutical Executive Europe - January 2008 - Pricing and Reimbursement: Through the Reimbursement Barriers (Page 27) Pharmaceutical Executive Europe - January 2008 - Generics: India Inc. (Page 28) Pharmaceutical Executive Europe - January 2008 - Generics: India Inc. (Page 29) Pharmaceutical Executive Europe - January 2008 - Generics: India Inc. (Page 30) Pharmaceutical Executive Europe - January 2008 - The Mix: New Models of Excellence (Page 31) Pharmaceutical Executive Europe - January 2008 - The Mix: New Models of Excellence (Page 32) Pharmaceutical Executive Europe - January 2008 - The Mix: New Models of Excellence (Page 33) Pharmaceutical Executive Europe - January 2008 - The Mix: New Models of Excellence (Page 34) Pharmaceutical Executive Europe - January 2008 - Last Word: Mid-size Matters (Page 35) http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091208http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091124http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091110http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091027http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091013http://digital.findpharma.com/nxtbooks/advanstaruk/PEE_DIGEST_20090930http://digital.findpharma.com/nxtbooks/advanstaruk/PEE_digest_20090916http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090902http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090825http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090819http://digital.findpharma.com//nxtbooks/advanstaruk/pee_digest_20090812http://digital.findpharma.com//nxtbooks/advanstaruk/pee_digest_20090805http://digital.findpharma.com//nxtbooks/advanstaruk/pee_digest_20090729http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090721http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090715http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090708http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090701http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090624http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090617http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090610http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090602http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090526http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090519http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090512http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090505http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_southafricahttp://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090429http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090422http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090415http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090408http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090401_v2http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090401http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090325http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090318http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090311http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090304http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090224http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090218http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090211http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090203http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090128http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090121http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090114http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope1008http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-ims1008http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0908http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0808http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0708http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0608http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-imssales0508http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0508http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0408http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0308http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0208http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-imssales0208http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0108http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-ims1207http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope1107http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope1007http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-imsoncology0907http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0407http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0307http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope1206http://www.nxtbookMEDIA.com

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.